has approved Dexcom G7 and FreeStyle Libres 2 and 3 for use during pregnancy. Both Dexcom and Libre can provide reliable and ...

the Libre 3. At the same time, Dexcom was building its own fully integrated CGM solution, and the final result was a game-changer: the Dexcom G7 (more on this later). Having used a total of five ...

Abbott said in the release it is on track to achieve a target of $10 billion in annual sales of FreeStyle Libre CGM systems by 2028. Dexcom, in a November 2024 third-quarter financial presentation ...

Baird acknowledged competitive risks from Abbott's Libre 3 and potential Medicare repricing but expects DexCom to deliver revenue growth of 10-15% and EPS growth of 20% over the next 2-3 years.